BIOMAT Database Logo BIOMAT Database Logo

Kidney transplantation under FK 506 immunosuppression. 1991

R Shapiro, and M Jordan, and J Fung, and J McCauley, and J Johnston, and Y Iwaki, and A Tzakis, and T Hakala, and S Todo, and T E Starzl
Department of Surgery, University of Pittsburgh, Pennsylvania.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D007165 Immunosuppression Therapy Deliberate prevention or diminution of the host's immune response. It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs. Antirejection Therapy,Immunosuppression,Immunosuppressive Therapy,Anti-Rejection Therapy,Therapy, Anti-Rejection,Therapy, Antirejection,Anti Rejection Therapy,Anti-Rejection Therapies,Antirejection Therapies,Immunosuppression Therapies,Immunosuppressions,Immunosuppressive Therapies,Therapies, Immunosuppression,Therapies, Immunosuppressive,Therapy, Immunosuppression,Therapy, Immunosuppressive
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006085 Graft Survival The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host. Graft Survivals,Survival, Graft,Survivals, Graft
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006937 Hypercholesterolemia A condition with abnormally high levels of CHOLESTEROL in the blood. It is defined as a cholesterol value exceeding the 95th percentile for the population. Hypercholesteremia,Elevated Cholesterol,High Cholesterol Levels,Cholesterol Level, High,Cholesterol Levels, High,Cholesterol, Elevated,Cholesterols, Elevated,Elevated Cholesterols,High Cholesterol Level,Hypercholesteremias,Hypercholesterolemias,Level, High Cholesterol,Levels, High Cholesterol
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor

Related Publications

R Shapiro, and M Jordan, and J Fung, and J McCauley, and J Johnston, and Y Iwaki, and A Tzakis, and T Hakala, and S Todo, and T E Starzl
Intestinal transplantation in children under FK 506 immunosuppression.
August 1993, Journal of pediatric surgery,
R Shapiro, and M Jordan, and J Fung, and J McCauley, and J Johnston, and Y Iwaki, and A Tzakis, and T Hakala, and S Todo, and T E Starzl
Lymphoproliferative disease after intestinal transplantation under primary FK 506 immunosuppression.
June 1994, Transplantation proceedings,
R Shapiro, and M Jordan, and J Fung, and J McCauley, and J Johnston, and Y Iwaki, and A Tzakis, and T Hakala, and S Todo, and T E Starzl
CMV infection in liver transplantation under cyclosporine or FK 506 immunosuppression.
December 1991, Transplantation proceedings,
R Shapiro, and M Jordan, and J Fung, and J McCauley, and J Johnston, and Y Iwaki, and A Tzakis, and T Hakala, and S Todo, and T E Starzl
Liver, kidney, and thoracic organ transplantation under FK 506.
September 1990, Annals of surgery,
R Shapiro, and M Jordan, and J Fung, and J McCauley, and J Johnston, and Y Iwaki, and A Tzakis, and T Hakala, and S Todo, and T E Starzl
Liver transplantation of American veterans under FK 506 immunosuppression: a preliminary report.
December 1991, Transplantation proceedings,
R Shapiro, and M Jordan, and J Fung, and J McCauley, and J Johnston, and Y Iwaki, and A Tzakis, and T Hakala, and S Todo, and T E Starzl
Optimal FK 506 dosage in patients under primary immunosuppression following liver transplantation.
January 1994, Transplant international : official journal of the European Society for Organ Transplantation,
R Shapiro, and M Jordan, and J Fung, and J McCauley, and J Johnston, and Y Iwaki, and A Tzakis, and T Hakala, and S Todo, and T E Starzl
Diabetes mellitus after renal transplantation under FK 506 (tacrolimus) as primary immunosuppression.
June 1996, Transplantation proceedings,
R Shapiro, and M Jordan, and J Fung, and J McCauley, and J Johnston, and Y Iwaki, and A Tzakis, and T Hakala, and S Todo, and T E Starzl
Limb transplantation in rats: immunosuppression with FK-506.
January 1995, The Journal of hand surgery,
R Shapiro, and M Jordan, and J Fung, and J McCauley, and J Johnston, and Y Iwaki, and A Tzakis, and T Hakala, and S Todo, and T E Starzl
FK 506-based immunosuppression in clinical pancreas transplantation.
December 1995, Transplantation proceedings,
R Shapiro, and M Jordan, and J Fung, and J McCauley, and J Johnston, and Y Iwaki, and A Tzakis, and T Hakala, and S Todo, and T E Starzl
Tacrolimus (FK 506) in kidney transplantation.
August 1998, Transplantation proceedings,
Copied contents to your clipboard!